FDA Approves Iyuzeh (latanoprost ophthalmic solution) for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension

In continuation of my update on  Latanoprost Thea Pharma, Inc.  (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical...